Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com
Videos
Photos, Logos and Downloads
-
The Harris Poll Survey Infographic
Many Americans are unaware of the risk of colorectal cancer based on new data from The Harris Poll. Read on to find out why screening is so important.
-
Cologuard analyzes both DNA alterations and blood in the stool to detect the presence of colon cancer and precancers. With Cologuard, patients can provide a sample in the privacy of their own home.
-
Cologuard is the first FDA-approved, noninvasive, stool-based DNA (sDNA) colorectal cancer screening test. Cologuard is intended for men and women 45 years or older at average risk for colorectal cancer.
